Department of Psychiatry & Mental Health and South African Medical Council Research Unit on Risk and Resilience in Mental Disorders, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
Department of Psychology, Yale University, New Haven, CT, USA.
BMC Psychiatry. 2021 Aug 9;21(1):392. doi: 10.1186/s12888-021-03363-3.
Treatment guidelines for generalized anxiety disorder (GAD) are based on a relatively small number of randomized controlled trials and do not consider patient-centered perceptions of treatment helpfulness. We investigated the prevalence and predictors of patient-reported treatment helpfulness for DSM-5 GAD and its two main treatment pathways: encounter-level treatment helpfulness and persistence in help-seeking after prior unhelpful treatment.
Data came from community epidemiologic surveys in 23 countries in the WHO World Mental Health surveys. DSM-5 GAD was assessed with the fully structured WHO Composite International Diagnostic Interview Version 3.0. Respondents with a history of GAD were asked whether they ever received treatment and, if so, whether they ever considered this treatment helpful. Number of professionals seen before obtaining helpful treatment was also assessed. Parallel survival models estimated probability and predictors of a given treatment being perceived as helpful and of persisting in help-seeking after prior unhelpful treatment.
The overall prevalence rate of GAD was 4.5%, with lower prevalence in low/middle-income countries (2.8%) than high-income countries (5.3%); 34.6% of respondents with lifetime GAD reported ever obtaining treatment for their GAD, with lower proportions in low/middle-income countries (19.2%) than high-income countries (38.4%); 3) 70% of those who received treatment perceived the treatment to be helpful, with prevalence comparable in low/middle-income countries and high-income countries. Survival analysis suggested that virtually all patients would have obtained helpful treatment if they had persisted in help-seeking with up to 10 professionals. However, we estimated that only 29.7% of patients would have persisted that long. Obtaining helpful treatment at the person-level was associated with treatment type, comorbid panic/agoraphobia, and childhood adversities, but most of these predictors were important because they predicted persistence rather than encounter-level treatment helpfulness.
The majority of individuals with GAD do not receive treatment. Most of those who receive treatment regard it as helpful, but receiving helpful treatment typically requires persistence in help-seeking. Future research should focus on ensuring that helpfulness is included as part of the evaluation. Clinicians need to emphasize the importance of persistence to patients beginning treatment.
广泛性焦虑障碍(GAD)的治疗指南基于相对较少的随机对照试验,且未考虑患者对治疗有效性的看法。我们调查了 DSM-5 GAD 及其两种主要治疗途径(单次治疗的有效性和既往无效治疗后继续寻求治疗的持久性)的患者报告治疗有效性的发生率和预测因素。
数据来自世界卫生组织(WHO)世界精神卫生调查中的 23 个国家的社区流行病学调查。使用完全结构化的 WHO 复合国际诊断访谈第 3.0 版(WHO Composite International Diagnostic Interview Version 3.0)评估 DSM-5 GAD。有 GAD 病史的受访者被问及是否接受过治疗,如果有,他们是否认为这种治疗有效。还评估了在获得有效治疗前看过的专业人士数量。平行生存模型估计了给定治疗被认为有效的概率和预测因素,以及既往无效治疗后继续寻求治疗的概率和预测因素。
总体 GAD 患病率为 4.5%,中低收入国家(2.8%)低于高收入国家(5.3%);34.6%的有 lifetime GAD 受访者报告曾接受过 GAD 治疗,中低收入国家(19.2%)的比例低于高收入国家(38.4%);3)70%接受过治疗的受访者认为治疗有效,中低收入国家和高收入国家的患病率相当。生存分析表明,如果患者坚持寻求多达 10 位专业人士的帮助,几乎所有患者都能获得有效的治疗。然而,我们估计只有 29.7%的患者会坚持那么久。个体层面获得有效治疗与治疗类型、共病惊恐障碍/广场恐怖症和儿童期逆境有关,但这些预测因素大多很重要,因为它们预测的是治疗的持久性,而非单次治疗的有效性。
大多数 GAD 患者未接受治疗。大多数接受治疗的患者认为治疗有效,但获得有效治疗通常需要坚持寻求治疗。未来的研究应重点确保将有效性纳入评估的一部分。临床医生需要向开始治疗的患者强调坚持治疗的重要性。